17-trifluoromethylphenyl trinor Prostaglandin F2α17-trifluoromethylphenyl trinor Prostaglandin F2α

221246-34-0

17-phenyl trinor prostaglandin F2α (17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma, with unsubstituted or meta-substituted aromatic derivatives being the most potent FP receptor agonists. 17-trifluoromethylphenyl trinor PGF2α, which contains an aromatic ring reminiscent of the trifluoromethyl-phenoxy ring in travoprost ((+)-fluprostenol isopropyl ester), is expected to act similarly to the free acid form of travoprost as an ocular hypotensive agent.

C24H31F3O5

456.502

Powder: -20℃ for 3 years. In solvent: -80℃ for 1 year.

DMSO: 25 mg/mLPBS(pH 7.2): 1 mg/mLDMF: 30 mg/mLEthanol: 50 mg/mL